Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ION904 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ION904 | EXPERIMENTAL | Up to 4 monthly doses of ION904 will be administered by subcutaneous (SC) injection. |
| Placebo | PLACEBO_COMPARATOR | Up to 4 monthly doses of placebo will be administered by SC injection. |
| Name | Type | Description |
|---|---|---|
| ION904 | DRUG | ION904 will be administered by SC injection. |
| Placebo | DRUG | Placebo will be administered by SC injection. |
General Inclusion Criteria: 1. Males must be surgically sterile or, abstinent or, if engaged in sexual relations with a woman of child-bearing potential (WOCBP), she uses a highly effective contraceptive method. Aged 18 - 75 inclusive and weighing ≥ 50 kilograms (kg) at the time of informed consent...
Top 9 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 5 | PHASE3 | Baxdrostat |
| Eli Lilly and Company | LLY | 4 | PHASE3 | Orforglipron, Clazakizumab |
| Alnylam Pharmaceuticals, Inc | ALNY | 2 | PHASE3 | Zilebesiran, ALN-AGT01 RVR |
| Mineralys Therapeutics, Inc. | MLYS | 1 | PHASE3 | lorundrostat |
| United Therapeutics Corporation | UTHR | 1 | PHASE3 | Ralinepag |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE2 | QCZ484, HJB647 |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE2 | iloperidone |
| Opus Genetics, Inc. | IRD | 1 | PHASE1 | OPGx-BEST1 |
| CRISPR Therapeutics AG | CRSP | 1 | PHASE1 | CTX340 |
ION904 is an investigational medicine being developed for the treatment of hypertension, or high blood pressure. It is designed for patients whose blood pressure is not adequately controlled. Ionis Pharmaceuticals is studying it as a monthly subcutaneous injection in adults 18 years and older.
ION904 targets angiotensinogen, abbreviated AGT. Angiotensinogen is the precursor protein at the start of the renin-angiotensin system, the hormonal pathway that regulates blood pressure. By targeting AGT, ION904 aims to reduce production of the angiotensin peptides that raise blood pressure.
ION904 is being developed by Ionis Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker symbol IONS. Ionis is the sponsor of the clinical program evaluating the drug in hypertension.
ION904 is in Phase 2 clinical development. It is investigational and has not been approved by the FDA. The Phase 2 study of ION904 in uncontrolled hypertension has been completed, and the program remains in clinical development.
ION904 has been evaluated in one clinical trial, NCT05314439, titled a study to assess the safety, tolerability, and efficacy of monthly subcutaneous administration of ION904 in participants with uncontrolled hypertension. That Phase 2 trial enrolled 48 participants in the United States, was randomized, double-blind, and placebo-controlled, and is now completed.
ION904 is administered as a monthly subcutaneous injection. The completed Phase 2 trial, NCT05314439, evaluated monthly subcutaneous dosing of ION904 in participants with uncontrolled hypertension, with 48 adults enrolled in the United States.